Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Abacavir
100%
AIDS Dementia Complex
100%
Antiretroviral Therapy
16%
Antiviral Efficacy
16%
Basal Resistance
16%
Beneficial Effects
16%
Cerebrospinal Fluid
33%
Complex Patients
50%
Design Phase
16%
Disease Activity
16%
Drug Resistance
16%
HIV RNA
33%
Immune Activation Markers
16%
Inefficacy
16%
Lack of Efficacy
16%
Neuropsychological Performance
16%
Outpatient Clinic
16%
Per Se
16%
Placebo
33%
Plasma HIV RNA
16%
Primary Outcome Measure
16%
Quinolinic Acid
16%
Randomized Placebo-controlled Trial
16%
Sample Size Calculation
16%
Soluble Tumor Necrosis Factor Receptor 2
16%
Trial Design
100%
β2-microglobulin (β2-MG)
33%
Nursing and Health Professions
Abacavir
100%
Antiretroviral Therapy
16%
Antivirus Agent
16%
Cerebrospinal Fluid
33%
Disease Activity
16%
Drug Resistance
16%
Efficacy
50%
HIV Associated Dementia
100%
Human Immunodeficiency Virus
50%
Outpatient Department
16%
Placebo
50%
Quinolinic Acid
16%
Sample Size
16%
Tumor Necrosis Factor Receptor 2
16%
Medicine and Dentistry
Abacavir
100%
Antiretroviral Therapy
16%
Antivirus Agent
16%
Cerebrospinal Fluid
33%
Disease Activity
16%
Drug Resistance
16%
HIV-associated Neurocognitive Disorder
100%
Human Immunodeficiency Virus
50%
Outpatient
16%
Placebo
50%
Quinolinic Acid
16%
Tumor Necrosis Factor Receptor 2
16%
Pharmacology, Toxicology and Pharmaceutical Science
Abacavir
100%
Antivirus Agent
16%
Disease Activity
16%
Drug Resistance
16%
HIV
50%
HIV Associated Dementia
100%
Placebo
50%
Quinolinic Acid
16%
Tumor Necrosis Factor Receptor 2
16%